Drug
Camrelizumab
Camrelizumab: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Camrelizumab 200mg NCT04203485 | Phase 3 | PD-L1 Positive Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Camrelizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.